Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 4/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.51 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30102042 | 0.98 | PARP10 (0.52) | PARP15PARP10PARP2LTA4HEPHX2 | |
| SCHEMBL23642692 | 0.97 | PARP15 (0.51) | PARP15PARP10PARP2LTA4HEPHX2 | |
| SCHEMBL19309189 | 0.94 | PARP10 (0.54) | PARP15PARP10PARP2LTA4HEPHX2 | |
| SCHEMBL23266204 | 0.94 | PARP15 (0.49) | PARP15PARP10PARP2LTA4HEPHX2 | |
| SCHEMBL23642869 | 0.87 | ACACB (0.46) | PARP15PARP10PARP2LTA4HEPHX2 | |
| SCHEMBL23642680 | 0.83 | LTA4H (0.45) | PARP15PARP10PARP2LTA4HEPHX2 | |
| SCHEMBL17050499 | 0.82 | PARP15 (0.53) | PARP15PARP10PARP2 | |
| SCHEMBL1391095 | 0.80 | PARP10 (0.59) | PARP15PARP10PARP2HPGDGRM2 | |
| SCHEMBL18406627 | 0.80 | PARP10 (0.59) | PARP15PARP10PARP2HPGDGRM2 | |
| SCHEMBL4508929 | 0.79 | HRH3 (0.60) | LTA4HEPHX2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398168-B2 | Preparation method of a glycoside compound | SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) | 2025-08-26 | — | — | US | disclosed |
| US-20220380399-A1 | PREPARATION METHOD OF A GLYCOSIDE COMPOUND | SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) | 2022-12-01 | — | — | US | disclosed |
| WO-2021139621-A1 | METHOD FOR PREPARING GLYCOSIDE COMPOUND | 上海和黄药业有限公司 | 2021-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398168-B2 | Preparation method of a glycoside compound | GALE, ST6GAL1, MGAM | PARP15 482/4885PARP10 657/4885PARP2 817/4885 |
| US-20220380399-A1 | PREPARATION METHOD OF A GLYCOSIDE COMPOUND | GALE, ST6GAL1, MGAM | PARP15 482/4885PARP10 657/4885PARP2 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.